Ultragenyx Pharmaceutical Inc - Company Profile
Powered by
All the data and insights you need on Ultragenyx Pharmaceutical Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Ultragenyx Pharmaceutical Inc Strategy Report
- Understand Ultragenyx Pharmaceutical Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
View up-to-date information on Ultragenyx Pharmaceutical Inc patents, including inventor and filing insights.
Patent Trends
Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
---|---|---|---|---|
IL294781A | Application | Gene therapy for treating cdkl5 deficiency disorder | A01K2217/075; A01K2227/105; A01K2267/0306; A61K35/761; A61K38/00; A61K48/005; A61K48/0058; A61K48/0075; C12N15/86; C12N2750/14143; C12N9/1205; C12Y207/11022 | September 01, 2022 |
EP4038194A1 | Application | VERFAHREN ZUR VERBESSERTEN THERAPEUTISCHEN VERWENDUNG VON REKOMBINANTEM AAV | A61K31/573; A61K45/06; A61P37/06; A61P43/00; C12N15/86; C12N2750/14143 | August 10, 2022 |
AU2021218703A1 | Application | Gene therapy for treating CDKL5 deficiency disorder | A01K2217/075; A01K2227/105; A01K2267/0306; A61K35/761; A61K38/00; A61K48/005; A61K48/0058; A61K48/0075; C12N15/86; C12N2750/14143; C12N9/1205; C12Y207/11022 | July 28, 2022 |
AU2021217143A1 | Application | Chaotropic agents for reducing formation of double-stranded RNA | A61P35/00; A61P43/00; C12Q1/6806 | July 21, 2022 |
US20220227703A1 | Application | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | C07B2200/05; C07B59/001; C07B59/002; C07C279/22; C07D213/82; C07D273/02; C07D498/10 | July 21, 2022 |
Top Inventors by Filings (Count by publication)
Name | Count |
---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer